Ovid Therapeutics Appoints Dr. Jeremy Levin as Chief Executive Officer
Levin joins Ovid Therapeutics to build a world-leading neurology company focused on rare and orphan diseases of the brain
NEW YORK – (BUSINESS WIRE) — April 16, 2015 – Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, today announced the appointment of Dr. Jeremy Levin as Chief Executive Officer. Dr. Levin has served as Chairman of Ovid since 2014 and will continue to serve in this role.
“I believe Ovid has tremendous potential and has been founded at a time when the science and medicine of neurology are at an inflection point. We believe we have the opportunity to create immense benefit for patients,” commented Dr. Levin. “I look forward to leading the company into an exciting future.”
Dr. Levin has more than 25 years of experience in the global pharmaceutical industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. Most recently, Dr. Levin served as President and CEO of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). Previously, he was a member of the Executive Committee of Bristol-Myers Squibb (NYSE: BMY) where he had global responsibilities for strategy, alliances and transactions. In this role, he devised and led BMY’s “String of Pearls” strategy, which resulted in the transformation of the company. Prior to BMY, he was Head of Global Business Development and Strategic Alliances at Novartis (NYSE: NVS). In this role, he established and managed strategic collaborations with multiple companies around the world. Dr. Levin has served on a number of public and private company boards, and currently serves on the Board of Directors of Biocon Ltd. (NSE: BIOCON) and privately-held ZappRx.
Dr. Levin is the recipient of a number of awards including the Kermode Prize for work on novel hypertension drugs, the Albert Einstein Award for Leadership in Life Sciences, the B’nai B’rith Award for Distinguished Achievement for commitment to improving global health care and the Officer’s Cross of the Order of Merit of the Republic of Hungary.
Dr. Levin holds a Bachelor’s Degree in Zoology and was awarded a Masters of Arts and a Doctorate in the structure of Chromatin from the University of Oxford. He also received Bachelor of Medicine and Bachelor of Surgery degrees from the University of Cambridge. He has practiced internal medicine at University Hospitals in England, Switzerland and South Africa.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a privately-held, New York based, biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain and few, if any, treatment options – patients who currently have no hope of cure or improvement. Ovid focuses on patients and their needs. Using the significant operational, product development and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development.
For more information on Ovid, please visit http://ovidrx.com.
For further information please contact:
Ovid Therapeutics Inc.
Dr. Anna Kazanchyan, SVP Product Development
(212) 776-4381, email@example.com
Burns McClellan, on behalf of Ovid Therapeutics
(212) 213-0006, ext. 327, firstname.lastname@example.org